Dissecting the contribution of O-Antigen and proteins to the immunogenicity of Shigella sonnei generalized modules for membrane antigens (GMMA).


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
13 01 2021
Historique:
received: 01 05 2020
accepted: 11 12 2020
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 18 8 2021
Statut: epublish

Résumé

GMMA are exosomes released from engineered Gram-negative bacteria resembling the composition of outer membranes. We applied the GMMA technology for the development of an O-Antigen (OAg) based vaccine against Shigella sonnei, the most epidemiologically relevant cause of shigellosis. S. sonnei OAg has been identified as a key antigen for protective immunity, and GMMA are able to induce anti-OAg-specific IgG response in animal models and healthy adults. The contribution of protein-specific antibodies induced upon vaccination with GMMA has never been fully elucidated. Anti-protein antibodies are induced in mice upon immunization with either OAg-negative and OAg-positive GMMA. Here we demonstrated that OAg chains shield the bacteria from anti-protein antibody binding and therefore anti-OAg antibodies were the main drivers of bactericidal activity against OAg-positive bacteria. Interestingly, antibodies that are not targeting the OAg are functional against OAg-negative bacteria. The immunodominant protein antigens were identified by proteomic analysis. Our study confirms a critical role of the OAg on the immune response induced by S. sonnei GMMA. However, little is known about OAg length and density regulation during infection and, therefore, protein exposure. Hence, the presence of protein antigens on S. sonnei GMMA represents an added value for GMMA vaccines compared to other OAg-based formulations.

Identifiants

pubmed: 33441861
doi: 10.1038/s41598-020-80421-y
pii: 10.1038/s41598-020-80421-y
pmc: PMC7806729
doi:

Substances chimiques

Antibodies, Bacterial 0
Antigens, Bacterial 0
Immunoglobulin G 0
O Antigens 0
Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

906

Références

Infect Immun. 2009 Dec;77(12):5572-82
pubmed: 19805538
Mol Cell Proteomics. 2018 Feb;17(2):205-215
pubmed: 29203497
PLoS Pathog. 2015 Mar 20;11(3):e1004749
pubmed: 25794007
ACS Omega. 2017 Nov 30;2(11):8282-8289
pubmed: 30023580
Vaccine. 2017 Jan 11;35(3):419-426
pubmed: 27998639
J Biol Chem. 2014 Sep 5;289(36):24922-35
pubmed: 25023285
Curr Opin Infect Dis. 2018 Oct;31(5):449-454
pubmed: 30048255
Vaccine. 2010 Mar 2;28(10):2231-2235
pubmed: 20056180
Front Immunol. 2017 Dec 22;8:1884
pubmed: 29375556
Lancet. 1997 Jan 18;349(9046):155-9
pubmed: 9111538
Carbohydr Res. 2014 Feb 19;385:1-8
pubmed: 24384528
Biotechnol J. 2019 Jan;14(1):e1800376
pubmed: 30537361
Hum Vaccin Immunother. 2020;16(1):197-205
pubmed: 31287754
PLoS One. 2017 Feb 13;12(2):e0172163
pubmed: 28192483
Vaccine. 2014 Mar 5;32(11):1273-9
pubmed: 24462403
Clin Vaccine Immunol. 2015 Apr;22(4):381-8
pubmed: 25651919
PLoS One. 2012;7(6):e35616
pubmed: 22701551
Int J Med Microbiol. 2016 Feb;306(2):99-108
pubmed: 26746581
PLoS One. 2015 Aug 06;10(8):e0134478
pubmed: 26248044
PLoS Negl Trop Dis. 2015 Jun 11;9(6):e0003708
pubmed: 26068698
EBioMedicine. 2017 Aug;22:164-172
pubmed: 28735965
Vaccine. 2019 Nov 28;37(50):7315-7327
pubmed: 28262332
J Immunol Methods. 2018 Oct;461:117-121
pubmed: 29969587
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5
pubmed: 10829079
mSphere. 2018 Mar 28;3(2):
pubmed: 29600284
Clin Vaccine Immunol. 2017 Feb 6;24(2):
pubmed: 27927680
Clin Vaccine Immunol. 2016 Dec 5;23(12):908-917
pubmed: 27581434
Science. 2005 Feb 25;307(5713):1313-7
pubmed: 15731456
Microbiology (Reading). 2009 Oct;155(Pt 10):3260-3269
pubmed: 19556292
Anal Biochem. 2013 Mar 1;434(1):136-45
pubmed: 23142430
Clin Vaccine Immunol. 2016 Apr 04;23(4):304-14
pubmed: 26865597
Hum Vaccin Immunother. 2019;15(6):1338-1356
pubmed: 31158047
Lancet Infect Dis. 2018 Nov;18(11):1229-1240
pubmed: 30266330
Front Immunol. 2019 Mar 08;10:335
pubmed: 30906291
Microbiol Spectr. 2019 Mar;7(2):
pubmed: 30953429

Auteurs

Francesca Mancini (F)

GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100, Siena, Italy.

Gianmarco Gasperini (G)

GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100, Siena, Italy.

Omar Rossi (O)

GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100, Siena, Italy.

Maria Grazia Aruta (MG)

GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100, Siena, Italy.

Maria Michelina Raso (MM)

GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100, Siena, Italy.

Renzo Alfini (R)

GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100, Siena, Italy.

Massimiliano Biagini (M)

GSK, Siena, Italy.

Francesca Necchi (F)

GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100, Siena, Italy.

Francesca Micoli (F)

GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100, Siena, Italy. francesca.x.micoli@gsk.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH